Sequent Asset Management LLC increased its holdings in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 33.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,000 shares of the biopharmaceutical company’s stock after acquiring an additional 2,000 shares during the period. Alexion Pharmaceuticals comprises about 0.8% of Sequent Asset Management LLC’s holdings, making the stock its 26th largest holding. Sequent Asset Management LLC’s holdings in Alexion Pharmaceuticals were worth $1,048,000 at the end of the most recent quarter.
A number of other institutional investors have also made changes to their positions in ALXN. Artisan Partners Limited Partnership lifted its stake in Alexion Pharmaceuticals by 220.9% in the 1st quarter. Artisan Partners Limited Partnership now owns 4,248,248 shares of the biopharmaceutical company’s stock worth $574,278,000 after acquiring an additional 2,924,550 shares in the last quarter. FMR LLC increased its position in Alexion Pharmaceuticals by 10.4% in the 1st quarter. FMR LLC now owns 29,144,320 shares of the biopharmaceutical company’s stock worth $3,939,729,000 after purchasing an additional 2,746,055 shares during the last quarter. Jennison Associates LLC increased its position in Alexion Pharmaceuticals by 17.3% in the 1st quarter. Jennison Associates LLC now owns 10,241,457 shares of the biopharmaceutical company’s stock worth $1,384,440,000 after purchasing an additional 1,512,545 shares during the last quarter. FIL Ltd increased its position in Alexion Pharmaceuticals by 629.3% in the 1st quarter. FIL Ltd now owns 1,208,567 shares of the biopharmaceutical company’s stock worth $163,373,000 after purchasing an additional 1,042,846 shares during the last quarter. Finally, Swedbank increased its position in Alexion Pharmaceuticals by 95.5% in the 2nd quarter. Swedbank now owns 1,429,397 shares of the biopharmaceutical company’s stock worth $187,222,000 after purchasing an additional 698,096 shares during the last quarter. 93.77% of the stock is owned by hedge funds and other institutional investors.
Several research analysts have weighed in on the company. Goldman Sachs Group reaffirmed a “neutral” rating and issued a $142.00 target price on shares of Alexion Pharmaceuticals in a research report on Thursday, May 23rd. BidaskClub lowered Alexion Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, July 31st. TheStreet raised Alexion Pharmaceuticals from a “c” rating to a “b” rating in a research report on Thursday, April 25th. Zacks Investment Research lowered Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, May 24th. Finally, ValuEngine lowered Alexion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 8th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and twelve have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $162.88.
Shares of NASDAQ ALXN traded up $3.15 during mid-day trading on Tuesday, reaching $111.84. 49,964 shares of the company traded hands, compared to its average volume of 2,212,457. The company has a current ratio of 4.04, a quick ratio of 3.56 and a debt-to-equity ratio of 0.26. The stock has a market cap of $24.66 billion, a PE ratio of 15.76, a PEG ratio of 1.05 and a beta of 1.65. The company’s fifty day moving average is $120.68. Alexion Pharmaceuticals, Inc. has a fifty-two week low of $92.56 and a fifty-two week high of $141.86.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings data on Wednesday, July 24th. The biopharmaceutical company reported $2.64 EPS for the quarter, beating the Zacks’ consensus estimate of $2.13 by $0.51. The business had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.18 billion. Alexion Pharmaceuticals had a return on equity of 20.23% and a net margin of 29.64%. The firm’s revenue for the quarter was up 15.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.07 EPS. As a group, sell-side analysts predict that Alexion Pharmaceuticals, Inc. will post 9 earnings per share for the current year.
In other news, Director Bros. Advisors Lp Baker sold 123,489 shares of the stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $126.53, for a total transaction of $15,625,063.17. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Indrani Lall Franchini sold 4,500 shares of the firm’s stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $132.78, for a total value of $597,510.00. Following the completion of the sale, the executive vice president now directly owns 29,627 shares in the company, valued at approximately $3,933,873.06. The disclosure for this sale can be found here. In the last three months, insiders have sold 428,567 shares of company stock worth $53,420,869. 4.08% of the stock is currently owned by insiders.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
Read More: What is a price target?
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.